Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
复制标题
DOI：
10.1111/j.1464-5491.2007.02333.x
复制
发表时间：
2008-02-01
影响因子：
3.5
通讯作者：
Madsbad, S.
中科院分区：
文献类型：
--
作者：
Vilsboll, T.;Brock, B.;Madsbad, S.
目的评价每日一次的人胰高血糖素样肽-1类似物利拉鲁肽对胰腺B细胞功能的影响。方法将39例2型糖尿病患者随机分为利拉鲁肽0.65、1.25、1.9 mg/d或安慰剂治疗14周。第一时相和第二时相的胰岛素释放通过胰岛素改良的频繁静脉葡萄糖耐量试验进行测量。在高血糖钳夹(20 mm o l/L)下测定精氨酸刺激的胰岛素分泌。结果1.25 mg/d和1.9 mg/d两个最高剂量的利拉鲁肽使胰岛素一相分泌分别增加118%和103%(P<；0.05)。与安慰剂组相比，只有1.25毫克/天组的第二时相胰岛素分泌显著增加。与安慰剂相比，精氨酸刺激的胰岛素分泌在两个最高剂量水平分别显著增加了114%和94%(P<；0.05)。结论利拉鲁肽治疗14周后，胰岛素分泌第一时相和第二时相均有改善，精氨酸刺激的胰岛素分泌在高血糖时也有所改善。
Aims To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function.Methods Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.Results The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05). Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo. Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05). There was no significant treatment effect on glucose effectiveness or insulin sensitivity.Conclusions Fourteen weeks of treatment with liraglutide showed improvements in first- and second-phase insulin secretion, together with improvements in arginine-stimulated insulin secretion during hyperglycaemia.